Neuroscience

Plant-based concept
#Botanical #Jaguar Health #License agreement #Neuroscience #Plant-based #Schizophrenia

Jaguar Health out-licenses plant-based drug for schizophrenia

Jaguar Health’s out-licensing agreement with Magdalena Biosciences to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded. The agreement now includes the ethnobotanical know-how related to development of a prescription drug compound from a specified medicinal plant for possible schizophrenia and psychoses indications and… Read More

#Business & Investment #News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  A leading news story this week has been the announcement of positive Phase II… Read More

#News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

This week in drug discovery (6-10 May) 

News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas. A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the… Read More

#News

Human brain
#Clinical trial #Neuroscience #Newron Pharmaceuticals #Schizophrenia

Study in schizophrenia patients shows positive top-line results 

Newron Pharmaceuticals has announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment.   The… Read More

#News

#Clinical trials #Concussion #Drug discovery #Neuroscience

Q&A: Developments in concussion therapies

DDW Editor Reece Armstrong speaks to Michael Wyand, Chief Executive Officer/Director, Oxeia Biopharmaceuticals about the development of the company’s treatment for concussion (OXE103) and the current lack of effective therapies for brain injuries.   RA: Tell us how OXE103 works?   MW: OXE103 (ghrelin) is a 28 amino acid neuro-peptide hormone… Read More

#Exclusive Content

#Blood brain barrier #Drug discovery #Neuroscience

Nutrient research reveals pathway for treating brain disorders 

Dr Rosemary Cater, a University of Queensland (UQ) researcher, has found molecular doorways that could be used to help deliver drugs into the brain to treat neurological disorders. Dr Carter from UQ’s Institute for Molecular Bioscience led a team which discovered that an essential nutrient called choline is transported into the… Read More

#News

#Brain injury #Cognitive impairment #Concussion #Neuroscience

Concussion drug therapies on the horizon

Michael Wyand, PhD, Chief Executive Officer/Director, Oxeia Biopharmaceuticals explains why there’s a need for new drugs to treat traumatic brain injuries. Whereas once it was thought that mild traumatic brain injuries were harmless and symptoms would disappear after a few days of rest, we now know that rest is not… Read More

#Exclusive Content

Brain inflammation
#Amyotrophic lateral sclerosis (ALS) #Axoltis Pharma #Blood brain barrier #Clinical trials #Neuroscience #Regulatory

Drug candidate for ALS patients authorised for Phase II trial

Axoltis Pharma has received authorisation from ANSM, the French agency for the safety of health products, to launch the SEALS study for Amyotrophic Lateral Sclerosis (ALS).   This Phase II clinical trial of drug candidate NX210c in patients with ALS is the first to target the integrity of the blood brain… Read More

#News #Regulatory

#Alta Neuroscience #Depression #Major depressive disorder #Neuroscience #Phase II trial

Major depressive disorder drug progresses to Phase II trials

Alto Neuroscience has initiated a Phase II study to determine the pharmacodynamic effects of ALTO-203 in major depressive disorder (MDD) patients, as well as assess its safety, tolerability, and pharmacokinetics. To date, ALTO-203 has demonstrated positive emotional and cognitive effects in healthy participants after a single… Read More

#News

#ALS #Autism #Neurology #Neuroscience #Schizophrenia

This week in drug discovery (1-5 April) 

News round-up for 1-5 April by DDW Digital Content Editor Diana Spencer. This has been a busy week in the field of neuroscience drug discovery, with EU approval for a long-acting schizophrenia treatment, research revealing new insights into autism, the formation of a partnership focused on ALS drug… Read More

#News

#European Commission #Neuroscience #Otsuka #Schizophrenia

EU approves long-acting injectable for schizophrenia

Abilify Maintena 960mg (aripiprazole) has been approved in the EU as the first once-every- two-months long-acting injectable for the maintenance treatment of schizophrenia. The new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months. Aripiprazole once-every-two-months LAI is a new formulation containing 960mg aripiprazole provided in a… Read More

#News #Regulatory

Neurons in the brain
#Autism #Neurodevelopmental disorders #Neuroscience #Rutgers Health

Study of autism types reveals common underlying mechanism

An analysis of how brains with different forms of autism develop has revealed common underlying mechanisms that may respond to existing medications. For the study, Rutgers Health researchers used induced pluripotent stem cells to transform the blood cells of people with both genetic and idiopathic autism… Read More

#News

#Alzheimer's #Amyotrophic lateral sclerosis (ALS) #Autism #Neurodegenerative disorders #Neuroscience #Parkinson's

New DDW Highlights podcast: 18 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon,… Read More

#News

#Alzheimer's #Amyotrophic lateral sclerosis (ALS) #Autism #Neurodegenerative disorders #Neuroscience #Parkinson's

This week in drug discovery (11-15 March) 

News round-up for 11-15 March by DDW Digital Content Editor Diana Spencer. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease. Read More

#News

#Allyx Therapeutics #Neurodegenerative disorders #Neuroscience #Phase I trial

Trial supports neurodegenerative disease-modifying drug

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon. The Phase Ib study examined the… Read More

#News

#Financing #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's

£25.2 million raised to progress Parkinson’s treatment

Mission Therapeutics has raised £25.2 ($32.1) million to accelerate development of its lead drug candidates in the area of mitophagy, MTX325 and MTX652, through clinical trials. The financing was jointly led by existing investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital. MTX325… Read More

#Business & Investment #News